<code id='D06F13DE9E'></code><style id='D06F13DE9E'></style>
    • <acronym id='D06F13DE9E'></acronym>
      <center id='D06F13DE9E'><center id='D06F13DE9E'><tfoot id='D06F13DE9E'></tfoot></center><abbr id='D06F13DE9E'><dir id='D06F13DE9E'><tfoot id='D06F13DE9E'></tfoot><noframes id='D06F13DE9E'>

    • <optgroup id='D06F13DE9E'><strike id='D06F13DE9E'><sup id='D06F13DE9E'></sup></strike><code id='D06F13DE9E'></code></optgroup>
        1. <b id='D06F13DE9E'><label id='D06F13DE9E'><select id='D06F13DE9E'><dt id='D06F13DE9E'><span id='D06F13DE9E'></span></dt></select></label></b><u id='D06F13DE9E'></u>
          <i id='D06F13DE9E'><strike id='D06F13DE9E'><tt id='D06F13DE9E'><pre id='D06F13DE9E'></pre></tt></strike></i>

          fashion

          fashion

          author:fashion    Page View:69
          The FDA building -- First Opinion coverage from STAT
          Adobe

          WASHINGTON — The Food and Drug Administration’s top cancer drug regulator doesn’t always ask for permission before taking on big initiatives.

          Richard Pazdur, director of the FDA Oncology Center of Excellence, hates bureaucracy. It stifles his ideas for getting treatments to cancer patients faster — of which there are many.

          advertisement

          To cut through that bureaucracy, Pazdur has a trick: “Don’t tell anybody,” he said to laughter at a meeting of the advocacy group Friends of Cancer Research Tuesday.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In
          Previous article: HHS names first
          Next article: Alkermes shareholders re

          comprehensive

          Alkermes shareholders re
          Alkermes shareholders re

          MarkLennihan/APAlkermesshareholdersvotedThursdaytore-electallofthedrugmaker’scurrentdirectors,ending

          read more
          Doudna institute plans to 'cure hundreds of diseases' with CRISPR
          Doudna institute plans to 'cure hundreds of diseases' with CRISPR

          ChristineKao/STATResearchersattendinggenetherapymeetingsoverthepastcoupleyearswereliabletobumpintoas

          read more
          Supreme Court strikes down use of affirmative action
          Supreme Court strikes down use of affirmative action

          ActivistsdemonstratedastheSupremeCourtheardoralargumentsonapairofaffirmativeactioncasesinOctober2022

          read more

          Readout LOUD podcast: FTC v. biotech, future of Pfizer and Vertex

          IsnoonesafefromtheFTC?HasPfizerbottomedout?Andisbiotechfinallyback?Wecoverallthatandmorethisweekon“T